Newsroom
Category
August 5, 2025
FOR IMMEDIATE RELEASE August 5, 2025 Contact: Eileen Teves, 210-450-7239, tevese@uthscsa.edu MEDIA ADVISORY UT Health San Antonio gears up to drive out childhood cancer Receives grant from Hyundai Hope on Wheels® to continue its fight against the disease WHAT: In the United States, 43 children are diagnosed with cancer every day. To help in the […]
July 17, 2025
FOXM1 protein identified as key driver in immunotherapy resistance, unlocking new therapeutic avenues For years, scientists have found the overexpression of a specific protein called FOXM1 in a wide range of cancers, including ovarian, breast and pediatric cancers. A recent study by scientists at The University of Texas Health Science Center at San Antonio […]
July 16, 2025
A cancer diagnosis is always devastating and is especially overwhelming when the patient is a child. This is why the CURE Childhood Cancer Foundation is on a mission to advance research that will bring an end to childhood cancers. Recently, Raushan Kurmasheva, PhD, assistant professor at the Greehey Children’s Cancer Research Institute and Department of […]
July 2, 2025
The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded $1.25 million by the Max and Minnie Tomerlin Voelcker Fund to support research projects being conducted by the institution’s early career investigators. Voelcker Fund Young Investigator Awards The Voelcker Fund Young Investigator Award will fund each recipient’s […]
July 2, 2025
The William and Ella Owens Medical Research Foundation recently awarded $1.5 million to The University of Texas Health Science Center at San Antonio (UT Health San Antonio) for research projects that address pancreatic cancer, Alzheimer’s disease and childhood cancers. This year, the foundation will fund $250,000 each to six research projects from UT Health […]
June 9, 2025
Scientists at The University of Texas Health Science Center at San Antonio have made one of the most important discoveries to date in the study and treatment of BRCA1-deficient cancers and drug resistance.
